Key facts
- Qlaris Bio’s last known valuation is $68.0M (Apr 2024).
- It has raised $55.0M across 4 recorded rounds; the latest was Seed Round ($3.9M) in Jun 2026.
- Notable investors include Correlation Ventures, Canaan Partners, Mayo Clinic, Mayo Clinic Ventures, New Leaf Venture — 6 tracked in total.
- Qlaris Bio has filed 3 Form Ds with the SEC since 2019, most recently Nov 2025 ($5.6M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Qlaris Bio
Funding rounds
4 roundsAbout Qlaris Bio
Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases. The company's therapies use novel mechanisms of action to potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive pediatric rare disease for which effective therapies remain elusive and limited, enabling physicians to get effective and novel therapies for the treatment.
- Sector
- Healthcare
- HQ
- Dedham, MA, United States
- Founded
- 2019
- Employees
- 10
- Website
- qlaris.bio/
- Ownership
- Privately Held (backing)
Qlaris Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qlaris Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qlaris Bio in its N-PORT filings yet. We sweep new filings monthly.